Megan E Capozzi, Richard D DiMarchi, Matthias H Tschöp, Brian Finan, Jonathan E Campbell. Endocr Rev 2018
Times Cited: 76
Times Cited: 76
Times Cited
Times Co-cited
Similarity
A rationally designed monomeric peptide triagonist corrects obesity and diabetes in rodents.
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
Brian Finan, Bin Yang, Nickki Ottaway, David L Smiley, Tao Ma, Christoffer Clemmensen, Joe Chabenne, Lianshan Zhang, Kirk M Habegger, Katrin Fischer,[...]. Nat Med 2015
47
Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
Juan Pablo Frias, Michael A Nauck, Joanna Van, Mark E Kutner, Xuewei Cui, Charles Benson, Shweta Urva, Ruth E Gimeno, Zvonko Milicevic, Deborah Robins,[...]. Lancet 2018
39
A new glucagon and GLP-1 co-agonist eliminates obesity in rodents.
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
Jonathan W Day, Nickki Ottaway, James T Patterson, Vasily Gelfanov, David Smiley, Jas Gidda, Hannes Findeisen, Dennis Bruemmer, Daniel J Drucker, Nilika Chaudhary,[...]. Nat Chem Biol 2009
30
Unimolecular dual incretins maximize metabolic benefits in rodents, monkeys, and humans.
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
Brian Finan, Tao Ma, Nickki Ottaway, Timo D Müller, Kirk M Habegger, Kristy M Heppner, Henriette Kirchner, Jenna Holland, Jazzminn Hembree, Christine Raver,[...]. Sci Transl Med 2013
27
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
Philip Ambery, Victoria E Parker, Michael Stumvoll, Maximilian G Posch, Tim Heise, Leona Plum-Moerschel, Lan-Feng Tsai, Darren Robertson, Meena Jain, Marcella Petrone,[...]. Lancet 2018
27
The New Biology and Pharmacology of Glucagon.
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
T D Müller, B Finan, C Clemmensen, R D DiMarchi, M H Tschöp. Physiol Rev 2017
26
The Sustained Effects of a Dual GIP/GLP-1 Receptor Agonist, NNC0090-2746, in Patients with Type 2 Diabetes.
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
Juan Pablo Frias, Edward J Bastyr, Louis Vignati, Matthias H Tschöp, Christophe Schmitt, Klara Owen, Rune Haubo Christensen, Richard D DiMarchi. Cell Metab 2017
23
Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
23
Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
S J Henderson, A Konkar, D C Hornigold, J L Trevaskis, R Jackson, M Fritsch Fredin, R Jansson-Löfmark, J Naylor, A Rossi, M A Bednarek,[...]. Diabetes Obes Metab 2016
21
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
Tamer Coskun, Kyle W Sloop, Corina Loghin, Jorge Alsina-Fernandez, Shweta Urva, Krister B Bokvist, Xuewei Cui, Daniel A Briere, Over Cabrera, William C Roell,[...]. Mol Metab 2018
21
Unimolecular Polypharmacy for Treatment of Diabetes and Obesity.
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
Matthias H Tschöp, Brian Finan, Christoffer Clemmensen, Vasily Gelfanov, Diego Perez-Tilve, Timo D Müller, Richard D DiMarchi. Cell Metab 2016
21
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1.
Daniel J Drucker. Cell Metab 2018
Daniel J Drucker. Cell Metab 2018
19
Islet α cells and glucagon--critical regulators of energy homeostasis.
Jonathan E Campbell, Daniel J Drucker. Nat Rev Endocrinol 2015
Jonathan E Campbell, Daniel J Drucker. Nat Rev Endocrinol 2015
18
Insulin Secretion Depends on Intra-islet Glucagon Signaling.
Berit Svendsen, Olav Larsen, Maria Buur Nordskov Gabe, Charlotte Bayer Christiansen, Mette M Rosenkilde, Daniel J Drucker, Jens Juul Holst. Cell Rep 2018
Berit Svendsen, Olav Larsen, Maria Buur Nordskov Gabe, Charlotte Bayer Christiansen, Mette M Rosenkilde, Daniel J Drucker, Jens Juul Holst. Cell Rep 2018
17
Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus.
M A Nauck, M M Heimesaat, C Orskov, J J Holst, R Ebert, W Creutzfeldt. J Clin Invest 1993
M A Nauck, M M Heimesaat, C Orskov, J J Holst, R Ebert, W Creutzfeldt. J Clin Invest 1993
17
Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
Piotr A Mroz, Brian Finan, Vasily Gelfanov, Bin Yang, Matthias H Tschöp, Richard D DiMarchi, Diego Perez-Tilve. Mol Metab 2019
17
β Cell tone is defined by proglucagon peptides through cAMP signaling.
Megan E Capozzi, Berit Svendsen, Sara E Encisco, Sophie L Lewandowski, Mackenzie D Martin, Haopeng Lin, Justin L Jaffe, Reilly W Coch, Jonathan M Haldeman, Patrick E MacDonald,[...]. JCI Insight 2019
Megan E Capozzi, Berit Svendsen, Sara E Encisco, Sophie L Lewandowski, Mackenzie D Martin, Haopeng Lin, Justin L Jaffe, Reilly W Coch, Jonathan M Haldeman, Patrick E MacDonald,[...]. JCI Insight 2019
17
Inhibition of gastric inhibitory polypeptide signaling prevents obesity.
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
Kazumasa Miyawaki, Yuichiro Yamada, Nobuhiro Ban, Yu Ihara, Katsushi Tsukiyama, Heying Zhou, Shimpei Fujimoto, Akira Oku, Kinsuke Tsuda, Shinya Toyokuni,[...]. Nat Med 2002
15
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.
Joachim Tillner, Maximilian G Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart,[...]. Diabetes Obes Metab 2019
Joachim Tillner, Maximilian G Posch, Frank Wagner, Lenore Teichert, Youssef Hijazi, Christine Einig, Stefanie Keil, Torsten Haack, Michael Wagner, Martin Bossart,[...]. Diabetes Obes Metab 2019
15
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes.
Brian Finan, Megan E Capozzi, Jonathan E Campbell. Diabetes 2020
Brian Finan, Megan E Capozzi, Jonathan E Campbell. Diabetes 2020
26
Reappraisal of GIP Pharmacology for Metabolic Diseases.
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
Brian Finan, Timo D Müller, Christoffer Clemmensen, Diego Perez-Tilve, Richard D DiMarchi, Matthias H Tschöp. Trends Mol Med 2016
15
Anti-Obesity Therapy: from Rainbow Pills to Polyagonists.
T D Müller, C Clemmensen, B Finan, R D DiMarchi, M H Tschöp. Pharmacol Rev 2018
T D Müller, C Clemmensen, B Finan, R D DiMarchi, M H Tschöp. Pharmacol Rev 2018
14
Glucagon-like peptide 1 (GLP-1).
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
T D Müller, B Finan, S R Bloom, D D'Alessio, D J Drucker, P R Flatt, A Fritsche, F Gribble, H J Grill, J F Habener,[...]. Mol Metab 2019
14
Gut hormone polyagonists for the treatment of type 2 diabetes.
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
Sara J Brandt, Anna Götz, Matthias H Tschöp, Timo D Müller. Peptides 2018
14
Glucagon increases energy expenditure independently of brown adipose tissue activation in humans.
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
V Salem, C Izzi-Engbeaya, C Coello, D B Thomas, E S Chambers, A N Comninos, A Buckley, Z Win, A Al-Nahhas, E A Rabiner,[...]. Diabetes Obes Metab 2016
13
Design of Novel Exendin-Based Dual Glucagon-like Peptide 1 (GLP-1)/Glucagon Receptor Agonists.
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda,[...]. J Med Chem 2017
Andreas Evers, Torsten Haack, Martin Lorenz, Martin Bossart, Ralf Elvert, Bernd Henkel, Siegfried Stengelin, Michael Kurz, Maike Glien, Angela Dudda,[...]. J Med Chem 2017
13
Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice.
R W Gelling, X Q Du, D S Dichmann, J Romer, H Huang, L Cui, S Obici, B Tang, J J Holst, C Fledelius,[...]. Proc Natl Acad Sci U S A 2003
R W Gelling, X Q Du, D S Dichmann, J Romer, H Huang, L Cui, S Obici, B Tang, J J Holst, C Fledelius,[...]. Proc Natl Acad Sci U S A 2003
13
11
GLP-1/glucagon receptor co-agonism for treatment of obesity.
Miguel A Sánchez-Garrido, Sara J Brandt, Christoffer Clemmensen, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp. Diabetologia 2017
Miguel A Sánchez-Garrido, Sara J Brandt, Christoffer Clemmensen, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp. Diabetologia 2017
11
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz,[...]. Diabetes Care 2016
Christof M Kazda, Ying Ding, Ronan P Kelly, Parag Garhyan, Chunxue Shi, Chay Ngee Lim, Haoda Fu, David E Watson, Andrew J Lewin, William H Landschulz,[...]. Diabetes Care 2016
11
Interrupted Glucagon Signaling Reveals Hepatic α Cell Axis and Role for L-Glutamine in α Cell Proliferation.
E Danielle Dean, Mingyu Li, Nripesh Prasad, Scott N Wisniewski, Alison Von Deylen, Jason Spaeth, Lisette Maddison, Anthony Botros, Leslie R Sedgeman, Nadejda Bozadjieva,[...]. Cell Metab 2017
E Danielle Dean, Mingyu Li, Nripesh Prasad, Scott N Wisniewski, Alison Von Deylen, Jason Spaeth, Lisette Maddison, Anthony Botros, Leslie R Sedgeman, Nadejda Bozadjieva,[...]. Cell Metab 2017
11
Emerging hormonal-based combination pharmacotherapies for the treatment of metabolic diseases.
Christoffer Clemmensen, Brian Finan, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp, Susanna M Hofmann. Nat Rev Endocrinol 2019
Christoffer Clemmensen, Brian Finan, Timo D Müller, Richard D DiMarchi, Matthias H Tschöp, Susanna M Hofmann. Nat Rev Endocrinol 2019
14
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist.
Francis S Willard, Jonathan D Douros, Maria Bn Gabe, Aaron D Showalter, David B Wainscott, Todd M Suter, Megan E Capozzi, Wijnand Jc van der Velden, Cynthia Stutsman, Guemalli R Cardona,[...]. JCI Insight 2020
Francis S Willard, Jonathan D Douros, Maria Bn Gabe, Aaron D Showalter, David B Wainscott, Todd M Suter, Megan E Capozzi, Wijnand Jc van der Velden, Cynthia Stutsman, Guemalli R Cardona,[...]. JCI Insight 2020
12
Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice.
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller, Susanna M Hofmann. Mol Metab 2017
Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D DiMarchi, Matthias H Tschöp, Timo D Müller, Susanna M Hofmann. Mol Metab 2017
12
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
10
MEDI0382, a GLP-1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single-dose, healthy-subject, randomized, Phase 1 study.
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, Marcella Petrone, Wenji Pu, Cristina Rondinone, Lutz Jermutus, Boaz Hirshberg. Br J Clin Pharmacol 2018
Philip D Ambery, Sebastian Klammt, Maximillian G Posch, Marcella Petrone, Wenji Pu, Cristina Rondinone, Lutz Jermutus, Boaz Hirshberg. Br J Clin Pharmacol 2018
19
Optimization of co-agonism at GLP-1 and glucagon receptors to safely maximize weight reduction in DIO-rodents.
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi, Mark D Erion, Jas Gidda, Nancy A Thornberry, Matthias H Tschöp,[...]. Biopolymers 2012
Jonathan W Day, Vasily Gelfanov, David Smiley, Paul E Carrington, George Eiermann, Gary Chicchi, Mark D Erion, Jas Gidda, Nancy A Thornberry, Matthias H Tschöp,[...]. Biopolymers 2012
10
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
10
3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial.
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
Carel W le Roux, Arne Astrup, Ken Fujioka, Frank Greenway, David C W Lau, Luc Van Gaal, Rafael Violante Ortiz, John P H Wilding, Trine V Skjøth, Linda Shapiro Manning,[...]. Lancet 2017
10
Treatment with LY2409021, a glucagon receptor antagonist, increases liver fat in patients with type 2 diabetes.
Cristina B Guzman, Xiaotian M Zhang, Rong Liu, Arie Regev, Sudha Shankar, Parag Garhyan, Sreekumar G Pillai, Christof Kazda, Naga Chalasani, Thomas A Hardy. Diabetes Obes Metab 2017
Cristina B Guzman, Xiaotian M Zhang, Rong Liu, Arie Regev, Sudha Shankar, Parag Garhyan, Sreekumar G Pillai, Christof Kazda, Naga Chalasani, Thomas A Hardy. Diabetes Obes Metab 2017
10
Reduced incretin effect in type 2 (non-insulin-dependent) diabetes.
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
M Nauck, F Stöckmann, R Ebert, W Creutzfeldt. Diabetologia 1986
10
Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease.
Darleen A Sandoval, David A D'Alessio. Physiol Rev 2015
Darleen A Sandoval, David A D'Alessio. Physiol Rev 2015
10
Liver-specific disruption of the murine glucagon receptor produces α-cell hyperplasia: evidence for a circulating α-cell growth factor.
Christine Longuet, Ana M Robledo, E Danielle Dean, Chunhua Dai, Safina Ali, Ian McGuinness, Vincent de Chavez, Patricia M Vuguin, Maureen J Charron, Alvin C Powers,[...]. Diabetes 2013
Christine Longuet, Ana M Robledo, E Danielle Dean, Chunhua Dai, Safina Ali, Ian McGuinness, Vincent de Chavez, Patricia M Vuguin, Maureen J Charron, Alvin C Powers,[...]. Diabetes 2013
10
Amino Acid Transporter Slc38a5 Controls Glucagon Receptor Inhibition-Induced Pancreatic α Cell Hyperplasia in Mice.
Jinrang Kim, Haruka Okamoto, ZhiJiang Huang, Guillermo Anguiano, Shiuhwei Chen, Qing Liu, Katie Cavino, Yurong Xin, Erqian Na, Rachid Hamid,[...]. Cell Metab 2017
Jinrang Kim, Haruka Okamoto, ZhiJiang Huang, Guillermo Anguiano, Shiuhwei Chen, Qing Liu, Katie Cavino, Yurong Xin, Erqian Na, Rachid Hamid,[...]. Cell Metab 2017
10
Intra-islet glucagon signaling is critical for maintaining glucose homeostasis.
Lu Zhu, Diptadip Dattaroy, Jonathan Pham, Lingdi Wang, Luiz F Barella, Yinghong Cui, Kenneth J Wilkins, Bryan L Roth, Ute Hochgeschwender, Franz M Matschinsky,[...]. JCI Insight 2019
Lu Zhu, Diptadip Dattaroy, Jonathan Pham, Lingdi Wang, Luiz F Barella, Yinghong Cui, Kenneth J Wilkins, Bryan L Roth, Ute Hochgeschwender, Franz M Matschinsky,[...]. JCI Insight 2019
10
Anti-obesity effects of GIPR antagonists alone and in combination with GLP-1R agonists in preclinical models.
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
Elizabeth A Killion, Jinghong Wang, Junming Yie, Stone D-H Shi, Darren Bates, Xiaoshan Min, Renee Komorowski, Todd Hager, Liying Deng, Larissa Atangan,[...]. Sci Transl Med 2018
10
Glucagon lowers glycemia when β-cells are active.
Megan E Capozzi, Jacob B Wait, Jepchumba Koech, Andrew N Gordon, Reilly W Coch, Berit Svendsen, Brian Finan, David A D'Alessio, Jonathan E Campbell. JCI Insight 2019
Megan E Capozzi, Jacob B Wait, Jepchumba Koech, Andrew N Gordon, Reilly W Coch, Berit Svendsen, Brian Finan, David A D'Alessio, Jonathan E Campbell. JCI Insight 2019
13
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
Steven P Marso, Stephen C Bain, Agostino Consoli, Freddy G Eliaschewitz, Esteban Jódar, Lawrence A Leiter, Ildiko Lingvay, Julio Rosenstock, Jochen Seufert, Mark L Warren,[...]. N Engl J Med 2016
10
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
Juan P Frías, Melanie J Davies, Julio Rosenstock, Federico C Pérez Manghi, Laura Fernández Landó, Brandon K Bergman, Bing Liu, Xuewei Cui, Katelyn Brown. N Engl J Med 2021
10
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
Frank L Greenway, Ken Fujioka, Raymond A Plodkowski, Sunder Mudaliar, Maria Guttadauria, Janelle Erickson, Dennis D Kim, Eduardo Dunayevich. Lancet 2010
9
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.